Xlife Sciences Shareholders Approve All Proposals at Annual General Meeting

Xlife Sciences AG (SIX: XLS) announced that shareholders approved all proposals presented at the company’s Annual General Meeting, where 3,134,367 voting shares, representing 54.3% of the total share capital, were represented. Chairman David L. Deck said the company strengthened its portfolio during the past year and highlighted the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform as key milestones supporting the next phase of growth.

According to the press release, the company also emphasized the strategic importance of the planned Landsteiner Scientific platform, which is intended to accelerate the identification and development of novel therapeutic approaches while improving global market access for Xlife Sciences’ portfolio companies. Management said the platform will integrate academic research with commercial development and serve as a cornerstone of the company’s future innovation pipeline, while also outlining upcoming capital markets activities.

The approval of all proposals signals strong shareholder confidence in Xlife Sciences’ strategy. The company, a Swiss incubator and accelerator focused on value development and commercialization of promising research projects from universities and research institutions in the life sciences sector, aims to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance.

The Nasdaq listing of Veraxa Biotech is a notable achievement, providing the portfolio company with access to deeper capital markets and increased visibility. The planned Landsteiner Scientific platform is expected to further enhance the company’s ability to identify and develop novel therapies, potentially improving patient outcomes and creating value for shareholders. As Xlife Sciences progresses with its capital markets activities, investors will be watching for further developments that could drive growth.

For more details, the full press release is available at https://ibn.fm/nfUvM.